MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
/PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the...